Moderna Company Insiders

Moderna's latest congressional trading

Moderna Management Team Effectiveness

The company has return on total asset (ROA) of (0.1549) % which means that it has lost $0.1549 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2932) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.22. The current year's Return On Capital Employed is expected to grow to -0.28. At present, Moderna's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 48.3 M, whereas Total Assets are forecasted to decline to about 9.6 B. The current year's Net Income Applicable To Common Shares is expected to grow to about 10.1 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 354.1 M. Moderna maintains a total of 390.73 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. On September 12, 2025, Representative Ro Khanna of US Congress acquired under $15k worth of Moderna's common stock. Some institutional investors establish a significant position in stocks such as Moderna in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Moderna, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Moderna Workforce Comparison

The company has Profit Margin (PM) of (1.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.26.

Moderna Insider Trading History

Moderna Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.